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Abstract
Background: Symptom based referral criteria for colorectal cancer (CRC) detection are the cornerstone of the strategy
to improve prognosis in CRC. In 2017, the National Institute for Health and Care Excellence (NICE) updated their referral
criteria (2017 NG12). Recently, several studies have evaluated the faecal haemoglobin (f-Hb) concentration in this
setting. The aim of this study is to evaluate the diagnostic accuracy of the 2017 NG12 referral criteria and to compare
them with the CG27 referral criteria, the f-Hb concentration and two f-Hb based prediction model: COLONPREDICT and
FAST Score.
Methods: This is a post-hoc diagnostic test study performed within the COLONPREDICT study database (1572 patients,
CRC prevalence 13.6%). We assessed symptoms, the 2017 NG12 and CG27 referral criteria and determined the f-Hb
before performing a colonoscopy. We compared the discriminatory ability using the area under the curve (AUC) and
the sensitivity and specificity at pre-stablished thresholds with the McNemar’s test.
Results: The 2017 NG12 referral criteria discriminatory ability (AUC 0.53; 95% confidence interval- CI 0.49–0.57) was
inferior to the CG27 version (AUC 0.59; 95% CI 0.55–0.63; p = 0.01), the f-Hb concentration (AUC 0.86; 95% CI 0.84–0-89;
p < 0.001), the COLONPREDICT Score (AUC 0.92; 95% CI 0.91–0.94; p < 0.001) or the FAST Score (AUC 0.87; 95% CI 0.85–
0.89; p < 0.001). The number of patients meeting each criteria were as follows: 2017 NG12 and CG27 = 94.1% and 52.
2%; f-Hb ≥20 and≥ 10 μg/g faeces = 38.6 and 44.3%; COLONPREDICT Score≥ 5.6 and≥ 3.2 = 29.4 and 63.2% and FAST
Score≥ 4.50 and≥ 2.12 = 37.1 and 87.0%. The 2017 NG12 criteria were more sensitive (100%) than the CG27 criteria (68.
2%), the f-Hb (≥20 μg/g) (91.2%), the f-Hb (≥10 μg/g) (93.5%), the COLONPREDICT Score (≥5.6) (90.1%) and the FAST
Score (≥4.50) (89.8%) (p ≤ 0.001) and equivalent to the COLONPREDICT Score (≥3.5) (99.5%) or the FAST Score (≥2.12)
(100.0%) (p = 1). However, their specificity (6.8%) was significantly lower than any of the evaluated criteria (50.3%, 69.6%,
63.4%, 78.7%, 45.8%, 71.3%, 13.9%; p < 0.001).
Conclusion: Referral criteria based on f-Hb measurement, either as a single test or within prediction models, are more
accurate than symptom-based referral criteria for CRC detection in symptomatic patients.
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Background
Colorectal cancer (CRC) is the third most common can-
cer worldwide and the second leading cause of cancer-
related death [1]. Two strategies are widely used to de-
tect the disease at an early stage and, thus, improve the
prognosis: CRC screening and early diagnosis strategies
in symptomatic patients [2, 3]. Although screening pro-
grammes have been progressively implemented, most
CRC are still detected when symptoms become apparent
[4]. In addition, although gastrointestinal symptoms are
extremely common in the population, the probability of
CRC detection associated with any one symptom is low
[5–7]. Thus, risk classification scores have been devel-
oped based on symptoms to determine which patients
are most at risk of CRC with the aim of reducing this
interval between the initial consultation and diagnostic
colonoscopy [8, 9].
In this regard, one of the best known referral criteria
for CRC detection are the National Institute for Health
and Care Excellence (NICE) referral guideline for sus-
pected cancer (CG27) [3]. This referral system has been
extensively evaluated showing a low specificity and a
variable sensitivity for CRC detection [6, 10–12]. In
order to improve these results, the updated version of
2015 (NG12) introduced two significant changes. First,
they recommended referral for those symptoms with a
positive predictive value of 3% instead of previous 5%.
Second, for the first time, testing for occult blood in fae-
ces was recommended in several symptom scenarios
with a positive predictive value below 3% [13]. However,
the guideline did not recommend any particular method
to determine occult blood in faeces.
Faecal immunochemical tests for haemoglobin (FIT)
allow for quantitation of faecal haemoglobin concentra-
tion (f-Hb). FIT has proven to be the best currently
available non-invasive test for CRC screening in asymp-
tomatic individuals and an excellent test for rule-in of
CRC and rule-out of significant colonic lesions (SCL) in
patients presenting with lower gastrointestinal symp-
toms [14–21]. On the basis of the available evidence
[22], the NICE diagnostic guidance (DG30) recommends
the use of FIT with a 10 μg Hb/g faeces to guide referral
for colorectal cancer in primary care [23]. However, the
effect of the NG12 is not well understood and only one
study has evaluated the diagnostic accuracy of this guid-
ance [24]. In July 2017, NG 12 was amended and testing
for occult blood in faeces was recommended in patients
without rectal bleeding but with unexplained symptoms
that do not meet the criteria for a suspected cancer
pathway [13].
We have recently developed and validated two f-Hb
based prediction models for CRC detection: COLON-
PREDICT and FAST. The database of the COLONPRE-
DICT Score derivation cohort [25, 26]. is an excellent
platform to compare the most widely symptom based re-
ferral criteria with the f-Hb concentration based strategies.
In this database, an extensive collection of information re-
garding symptoms as well as several blood and faecal de-
terminations are included. This information allowed us to
perform a post hoc analysis in order to evaluate the diag-
nostic accuracy of the 2017 NG12, compare these criteria
with the CG27, the f-Hb concentration and two CRC
prediction models based on the f-Hb concentration:
COLONPREDICT and FAST Scores [25, 26].
Methods
Study design
The current study is a post hoc analysis performed within
the COLONPREDICT study: a multicentre, cross-sectional,
blinded study of diagnostic tests. The study aimed to create
and validate a CRC prediction index based on available bio-
markers, clinical and demographical data. We performed
this post hoc analysis in the 1572 patients included in the
derivation previously described [25].
Brief description of the COLONPREDICT study
The details of the study have been described extensively
elsewhere and are summarized here [25, 26]. We used
the Colonoscopy Research into Symptom Prediction
questionnaire (CRISP) to record symptoms and demo-
graphic data [27]. Based on this questionnaire, they de-
termined if patients met the CG27 referral criteria for
CRC detection [3]. f-Hb concentration was assessed
using the automated OC-SENSOR MICRO analyser
(Eiken Chemical Co., Ltd., Tokyo, Japan). The faeces for
the f-Hb determination were collected using the
OC-Sensor probe. Moreover, we determined blood
haemoglobin (b-Hb) and mean corpuscular volume with
a Beckman Coulter Autoanalyzer (Beckman Coulter Inc.,
CA, USA). Colonoscopy was performed blind for the
questionnaire and analytical results.
2017 NG12 referral criteria and the f-Hb based prediction
models calculation
On the basis of the information obtained from the CRISP
questionnaire and the analysis performed (f-Hb, b-Hb and
mean corpuscular volume), we determined which of the
2017 NG12 criteria for CRC suspicion were met. Two re-
searchers (JMH and JC) independently decided the
equivalence between each NICE criteria and the informa-
tion collected. Finally, they reached a consensus version.
NG12 referral criteria are shown in Table 1 [13]. We con-
sidered a positive faecal occult blood test if the f-Hb con-
centration was ≥10 μg Hb/g faeces.
COLONPREDICT score is a CRC prediction model
based on a multivariable logistic regression analysis [25].
The COLONPREDICT score is based in eleven variables
and the mathematical formula is as follows: 0.789 x
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rectal bleeding + 0.536 x change in bowel habit + 2.694 x
rectal mass − 1.283 x benign anorectal lesions + 2.831 x
f-Hb ≥20 μg Hb/g faeces + 1.561 x b-Hb (< 10 g/dL) +
0.588 x b-Hb (10–12 g/dL) + 1.511 x CEA ≥3 ng/mL +
0.040 x age (years) + 0.813 x sex (male) -2.073 x previous
colonoscopy (last 10 years) -0.849 x continuous treat-
ment with aspirin. It shows a high diagnostic accuracy
for CRC detection. Two thresholds have been defined
with 90% and 99% sensitivity for CRC: 5.6 and 3.5.
FAST Score is a CRC prediction model based on a
multivariable logistic regression analysis [26]. The FAST
score is based on three variables and the mathematical
formula is as follows: 0 x f-Hb (0) μg Hb/g faeces 0.684
x f-Hb (1, 19) + 2.824 x f-Hb [20, 200) μg Hb/g faeces +
4.184 x f-Hb ≥200 μg Hb/g faeces + 0.031 x age (years)
+ 0.479 x sex (male). Two thresholds have been defined
with 90% and 99% sensitivity for CRC: 4.50 and 2.12.
Outcomes
The main outcome was CRC detection. According to pre-
vious studies evaluating FIT in symptomatic patients,
[14–21] we considered significant colonic lesion (SCL) de-
tection as the secondary outcome. We defined SCL as
CRC, advanced adenoma (≥10 mm, villous histology,
high-grade dysplasia), polyposis (> 10 polyps of any hist-
ology, including serrated lesions), histologically confirmed
colitis (any aetiology), polyps ≥10 mm, complicated diver-
ticular disease (diverticulitis, bleeding), colonic ulcer and/
or bleeding angiodysplasia.
Statistical analysis
First, we performed a descriptive analysis of the popula-
tion included in the study. In order to determine differ-
ences in diagnostic accuracy between the NG12 referral
criteria and the rest of diagnostic criteria, the CG27 re-
ferral criteria, the f-Hb concentration, the COLONPRE-
DICT and the FAST score we performed two analysis.
First, we determined the number of individuals with a
positive result and the sensitivity and the specificity for
CRC and SCL detection. We determined if the differ-
ences between the sensitivity and the specificity of the
NG12 referral criteria and the rest of diagnostic criteria,
CG27 referral criteria, the COLONPREDICT and the
FAST scores at the pre-stablished thresholds and the
f-Hb at a 10 and 20 μg Hb/g faeces concentration
threshold, were statistically significant using the McNe-
mar’s test. Finally, we also calculated the positive and
negative predictive value (PPV, NPV), the positive and
negative likelihood ratios (LR) and the diagnostic Odds
Ratio (OR) of all the diagnostic tests. Diagnostic OR is
defined as the odds of positivity in subjects with disease
relative to the odds in subjects without disease.
In a second step, we evaluated the discriminatory abil-
ity using receiver-operating characteristic (ROC) curves
for CRC and SCL diagnosis, and we calculated the area
under the curve (AUC). We determined whether there
were statistically significant differences using the
chi-square test of homogeneity of areas. Additionally, we
determined if there were differences in the discrimin-
atory ability of each of the diagnostic criteria according
to the healthcare level referring the patient to colonos-
copy. Primary healthcare referral was determined when
a general practitioner was requesting the colonoscopy
and secondary healthcare referral was determined when
a specialist (gastroenterologist, surgeon..) was requesting
the exploration.
We report differences with 95% confidence intervals
(CI) and their significance. We consider a p-value < 0.05
statistically significant. We carried out the analyses using
the IBM SPSS Statistics for Windows version 21.0 (IBM
Corp, Armonk, USA) and EPIDAT 3.1 (Dirección Xeral
de Saúde Pública, Santiago de Compostela, Spain).
Results
Description of the cohort
Among the 1572 patients included in the derivation co-
hort of the COLONPREDICT, a CRC was detected in 214
(13.6%) patients and a SCL in 463 (29.5%) patients: ad-
vanced adenomas in 251 (16.0%), a polyp ≥10 mm with
non-adenoma histology in 6 (0.4%), colitis in 36 (2.3%)
and other SCLs in 6 (0.4%) patients. Direct referrals from
primary care to endoscopic evaluation accounted for
22.9% of the patients included.
Table 1 Criteria to refer people using a suspected cancer
pathway referral for CRC according to the NG12 referral criteria.
The number of patients meeting each of the referral criteria is
shown
Criteria Number of
patients
(n = 1572)
Patients ≥40 years with unexplained weight loss and
abdominal pain
196 (12.5%)
Patients ≥50 years with unexplained rectal bleeding 811 (51.6%)
Patients ≥60 years with: iron–deficiency anaemia or
changes in their bowel habit
890 (56.7%)
Patients with a rectal or abdominal mass 80 (5.1%)
Adults < 50 years with rectal bleeding and any of the
following unexplained symptoms or findings:
abdominal pain, change in bowel habit, weight loss or
iron-deficiency anaemia.
124 (7.9%)
Offer testing for occult blood in faeces to assess for
colorectal cancer in adults without rectal bleeding who
but with unexplained symptoms that do not meet the
criteria for a suspected cancer pathway referral
A positive test for occult blood in faeces was
considered if the haemoglobin concentration was
≥10 μg Hb/g faeces.
78 (4.9%)
Any of the referral criteria 1479 (94.1%)
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As we show in the Table 1, 1,479 out of the 1572
(94.1%) met at least one of the 2017 NG12 referral cri-
teria. In contrast, 52.2% of the patients met any of the
CG27 referral criteria, 38.7% had a f-Hb concentration ≥
20 μg Hb/g faeces, 44.4% had a f-Hb concentration ≥
10 μg Hb/g faeces, 30.9% had a COLONPREDICT
Score ≥ 5.6, 60.5% had a COLONPREDICT Score ≥ 3.5,
37.1% had a FAST Score ≥ 4.50 and 88.0% had a FAST
Score ≥ 2.12.
Analysis of the diagnostic accuracy
The sensitivity of the 2017 NG12 referral criteria for
CRC detection reaches 100% at the expense of a low
specificity (6.8%). As we show in the Table 2, the sensi-
tivity of the 2017 NG12 referral criteria is superior to
the sensitivity of the CG27 referral criteria, the f-Hb
(≥20 μg Hb/g and ≥ 10 μg Hb/g faeces), the COLON-
PREDICT Score at a 5.6 threshold (p < 0.001) and the
FAST Score at a 4.50 threshold. In contrast, the sensitiv-
ity is similar to the COLONPREDICT Score at a 3.2
threshold and the FAST Score at a 2.12 threshold (p = 1)
and the specificity is inferior to any of the other criteria
(p < 0.001). The rest of the diagnostic accuracy analysis
is displayed in Table 2.
On the other hand, 2017 NG12 referral criteria allows
the diagnosis of 98.9% of SCL. As in the diagnostic ac-
curacy for CRC detection, the specificity is extremely
low (7.9%). As we show in the Table 3, the sensitivity of
the 2017 NG12 referral criteria is similar to the FAST
Score at a 2.12 threshold (p = 1) and superior the rest of
the evaluated criteria. In contrast, the specificity of the
2017 NG12 criteria is inferior to any of the additional cri-
teria evaluated (p < 0.001). We show the PPV, NPV, posi-
tive and negative LR and the diagnostic OR in Table 2.
Analysis of the discriminatory ability
The analysis of the discriminatory ability for CRC detec-
tion of the NICE referral criteria, the f-Hb concentra-
tion, the COLONPREDICT and the FAST Score is
shown in Fig. 1. The discriminatory ability of the 2017
NG12 referral criteria is inferior to any of the evaluated
criteria in the Chi-square homogeneity test comparison
of AUC. Additionally, we found no differences in the
performance of each diagnostic test in the evaluation of
the discriminatory ability according to the healthcare re-
ferring the patient to colonoscopy: 2017 NG12 referral
criteria (primary = 0.53, 95% CI 0.46–0.60; secondary =
0.53, 95% CI 0.48–0.58; p = 0.1), CG27 referral criteria
(primary = 0.60, 95% CI 0.54–0.66; secondary = 0.59, 95%
CI 0.55–0.63; p = 0.7), f-Hb concentration (primary =
0.85, 95% CI 0.80–0.89; secondary = 0.86, 95% CI 0.83–
0.89; p = 0.5), COLONPREDICT Score (primary = 0.90,
95% CI 0.86–0.94; secondary = 0.93, 95% CI 0.91–0.95;
p = 0.1), FAST Score (primary = 0.84, 95% CI 0.79–0.89;
secondary = 0.88, 95% CI 0.85–0.90; p = 0.1). Fig. 2
shows the discriminatory ability for SCL detection of the
diagnostic tests evaluated. The discriminatory ability of
the 2017 NG12 referral criteria is similar to the CG27
referral criteria and inferior to the rest of the evaluated
criteria in the Chi-square homogeneity test comparison
of AUC.
Discussion
Summary
We have evaluated the diagnostic accuracy of the 2017
NG12 referral criteria for suspected CRC. As we clearly
show, these updated criteria are more sensitive than
CG27 version. However, they produce a marked increase
in the number of patients meeting them and a reduction
in the specificity. Furthermore, we had the opportunity
to compare them with the f-Hb concentration and two
f-Hb based prediction model. As we clearly show, both
diagnostic tools have a higher discriminatory ability than
the NICE referral criteria.
Strengths and limitations
We have used a wide cohort of consecutive patients re-
ferred to colonoscopy due to gastrointestinal symptoms.
Patients were evaluated homogenously using a symptom
questionnaire and several analytics, including a FIT, were
performed before colonoscopy. This questionnaire
allowed us to gather all the details regarding type of
symptoms, duration and evolution. Thus, we could
evaluate the 2017 NG12 referral criteria for suspected
CRC for the first time. Furthermore, we have been able
to evaluate the use of FIT, with the 10 μg Hb/g faeces,
as recommended in the DG30 [23]. On the other hand,
our study has several limitations that must be taken in
consideration. We cannot exclude a risk of bias of selec-
tion, as long as the symptomatic patients included in the
study were previously selected for colonoscopy evalu-
ation. However, we have included all consecutive pa-
tients referred both from primary and secondary
healthcare to colonoscopy.
Comparison with existing literature
The update of the NICE referral criteria is based on re-
ducing the PPV threshold required to refer patients from
primary care using a suspected cancer pathway referral.
The guideline development group agreed to use a
threshold value of 3% PPV to underpin their recommen-
dations [13]. So, those patients with symptoms (i.e ≥
40 years with unexplained weight loss) with a PPV > 3%
for CRC should be referred for further testing. Our re-
sults clearly demonstrate that this strategy increases the
sensitivity for CRC detection in comparison with previ-
ous criteria. However, these criteria certainly introduce a
risk of over investigation. In fact, what our analysis
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confirms is that the discriminatory ability of any group
of symptoms for CRC detection is suboptimal [6].
An additional innovation of the 2017 NG12 referral
criteria is the inclusion of the faecal occult blood test in
the evaluation of symptomatic patients. However, its use
is only limited to patients without rectal bleeding and
with unexplained symptoms that do not meet the cri-
teria for a suspected cancer pathway referral [13]. Our
results confirm the data previously published: the f-Hb
concentration measured with a FIT shows a higher dis-
criminatory ability for CRC detection than the NICE re-
ferral criteria [14–19]. So, probably, the strategy for the
evaluation of the risk of CRC detection in symptomatic
patients should be based on the f-Hb concentration irre-
spective of symptoms. Actually, in the COLONPRE-
DICT Score, patients with a f-Hb concentration ≥ 20 μg
Hb/g faeces have 17.0 times more risk of CRC detection.
In contrast, patients with rectal bleeding or a change in
bowel habit have 2.2 and 1.7 times more risk of CRC de-
tection, respectively [25].
Recently, an article has evaluated the diagnostic accur-
acy of the 2017 NG12 referral criteria for CRC and SCL
detection and compared these criteria with the f-Hb
concentration [24]. This study used the database of three
diagnostic tests studies evaluating FIT in symptomatic
patients [15, 17, 19]. and shows that the discriminatory
ability of the 2017 NG12 referral criteria are inferior to
the f-Hb concentration. This cohort has significant dif-
ferences with ours: the prevalence of symptoms related
to CRC diagnosis, rectal bleeding, changes in bowel
habit, iron-deficiency anaemia or rectal mass, is inferior
as well as the prevalence of CRC or SCL. Probably, these
differences are responsible for the differences in the
number of patients that meet 2017 NG12 referral cri-
teria and in the inferior discriminatory ability docu-
mented in our study. However, are results are consistent
Fig. 1 ROC curves of the NICE referral criteria, faecal haemoglobin concentration and the COLONPREDICT and FAST Scores for colorectal cancer
detection. The area under the curve of the ROC curves are shown. 1Significance of the discriminatory ability differences when compared with the
NG12 referral criteria in Chi square homogeneity test. Differences with p < 0.05 are considered statistically significant. ROC, Receiver-operating
characteristics; NICE, National Institute for Health and Care Excellence
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in the comparison of the 2017 NG12 referral criteria
with the f-Hb concentration.
Implications for research and/or practice
One of the main lessons learned in these years from the
CRC screening programs is that lack of symptoms or the
presence of non-specific symptoms do not exclude a
CRC in adult population. Up to 20% of the incident
CRC are detected in asymptomatic patients within a
CRC screening program based in a guaiac faecal occult
blood test [4]. So, the strategies for CRC detection in
symptomatic patients should determine which patients
require urgent referral, which require a normal referral
and, finally, in what situations no additional evaluation
is required. The NICE referral criteria only determine
the scenarios where an urgent referral is required. Due
to the increased discriminatory ability of the FIT for
CRC, either the f-Hb concentration alone or a f-Hb
based prediction model can allow to establish these
three risk groups with different diagnostic strategies.
As we have recently proposed, at least 90% of CRC
should be detected in a high-risk group, requiring a
fast-track referral to colonoscopy. In contrast, in a
low-risk group, where no additional explorations are
required, the probability of a missing CRC should be
well below 1%, so that the risk of CRC is balanced
with the risk of colonoscopy complications, mainly
perforation [28].
Conclusions
To conclude, the discriminatory ability of any symptom
based criteria is limited when compared with a f-Hb
concentration based strategy. An urgent evaluation of
the diagnostic accuracy of FIT in symptomatic patients
attending primary care is required.
Fig. 2 ROC curves of the NICE referral criteria, faecal haemoglobin concentration and the COLONPREDICT and FAST Scores for significant colonic
lesion detection. The area under the curve of the ROC curves are shown. 1Significance of the discriminatory ability differences when compared
with the NG12 referral criteria in Chi square homogeneity test. Differences with p < 0.05 are considered statistically significant. ROC, Receiver-
operating characteristics; NICE, National Institute for Health and Care Excellence
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